ArticleACS omega2025
Unraveling Common Patterns and Differences among Cruzipains through Molecular Dynamics Simulations and Structural Analyses.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates.Chemical biology & drug design · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease (CD) is a neglected tropical disease for which novel and improved treatments are needed. The cysteine protease Cruzipain is one of the main targets for the development of novel drugs for the treatment of CD. Recent bioinformatics analyses have revealed four Cruzipain subtypes whose active sites differ in key positions for ligand recognition. These analyses suggest a possible effect on the substrate specificity and affinity for ligands. To better investigate the impact of substitutions in Cruzipain subtypes, we employed molecular dynamics simulations and varied structural analyses on representatives of each Cruzipain subtype. Our results indicated that the substitutions did not significantly affect the overall flexibility and conformation of these proteases. In contrast, we observed differences in their active site characteristics, including different electrostatic potentials, cavity volumes, and patterns of interactions with the virtual probes. The distinct alterations in the active site subsites, especially in the S2 subsite, suggest unique functional changes that could affect substrate binding, ligand recognition, and possibly enzymatic effectiveness in various biological situations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.